<DOC>
	<DOCNO>NCT02214563</DOCNO>
	<brief_summary>The purpose study determine whether cholecalciferol supplementation decrease blood concentration hepcidin-25 hemodialysis patient .</brief_summary>
	<brief_title>Cholecalciferol Supplementation Anemia Mineral Bone Disorder Hemodialysis Patients</brief_title>
	<detailed_description>There 4 arm study : ( 1 ) Thrice-weekly cholecalciferol supplementation ( 3,000 IU ) , ( 2 ) Monthly cholecalciferol supplementation ( equivalent 9,000/week ) , ( 3 ) Thrice-weekly placebo , ( 4 ) Monthly placebo . The primary analysis do regard 2 cholecalciferol group 2 placebo group one group , evaluate effect cholecalciferol regardless supplementation regimen . As secondary analysis , examine difference thrice-weekly once-monthly supplementation regimen .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Bone Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Patients endstage renal disease receive thriceweekly maintenance hemodialysis On treatment erythropoietin stimulate agent With write informed consent On treatment epoetin beta pegol ESA On supplementation native vitamin D Hypercalcemia ( &gt; =10.5 mg/dL correct serum calcium ) On treatment intravenous iron agent Judged ineligible randomize study investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Vitamin D</keyword>
	<keyword>Cholecalciferol</keyword>
	<keyword>Hepcidins</keyword>
	<keyword>Renal Dialysis</keyword>
</DOC>